Delivery systems for acute migraine medications

Canadian Family Physician

Volumn 47, Issue FEB., 2001, Pages 322-329

  Worthington, Irene ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT;

ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; GENERAL PRACTITIONER; HUMAN; INJECTION PAIN; MEDICAL INFORMATION; MIGRAINE; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; REVIEW; TASTE DISORDER;

ACUTE DISEASE; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANALGESICS; DRUG DELIVERY SYSTEMS; HUMANS; INFUSIONS, INTRAVENOUS; MIGRAINE DISORDERS; NAUSEA; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; VOMITING;

EID: 0035105245     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence: a review of population-based studies. Neurology 1994;44(6 Suppl 4):S17-S23.
2. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: a national probability sample. Headache 1992;32:237-8.
3. Hamalainen ML. Migraine in children. Guidelines for treatment. Central Nerv System Drugs 1998;10:105-17.
4. Pryse-Phillips WEM, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Can Med Assoc J 1997;156:1273-87.
5. Dahlof CGH, Solomon G. The burden of migraine to the individual sufferer: a review. Eur J Neurol 1998;5:525-33.
6. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993;20:131-7.
7. De Lissvoy G, Lazarus SS. The economic cost of migraine: present state of knowledge. Neurology 1994;44(Suppl 4):S56-S62.
8. Pryse-Phillips WEM, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, et al. Guidelines for the nonpharmacologic management of migraine in clinical practice. Can Med Assoc J 1998;159:47-54.
9. Dahlof C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-71.
10. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999;39(Suppl 2):S20-6.
11. Gruffydd-Jones K, Hood CA, Price DB. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia 1997;17:31-6.
12. Klapper JA, Stanton J. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache 1992;32:21-3.
13. Becker WJ, Riess CM, Hoag J. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache 1996;36:144-8.
14. Weisz MA, El-Raheb M, Blumenthal HJ. Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache 1994;34:371-3.
15. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998;18:532-8.
16. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack. Results of a double-blind, placebo-controlled trial. Arch Intern Med 1998;158:1013-8.
17. Peatfield RC. Migraine: which triptan? Hosp Med 1999;60:277-80.
18. Worthington I. Current migraine therapy. Can J Clin Pharmacol 1996;3:39-51.
19. MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993;13:124-7.
20. Sawynok J, Yaksh TL. Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev 1993;45:43-85.
21. Fuseau E, Webster C, Asgharnejad M, Huffman C. Naratriptan oral pharmacokinetics in migraine subjects [abstract]. J Neural Sci 1997;150(Suppl):S33.
22. Thomsen LL, Dixon R, Lassen LH, Gibbens M, Langemark M, Bendtsen L, et al. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996;16:270-5.
23. Meloche J. Triptans and migraine: which drug for which patient? Can J Diagnosis 1999;Jan:67-77.
24. 1 receptor agonists for migraine: comparative considerations. Formulary 1999;34:324-8.
25. Derman HS, Derman BR, DeSaibro L, Hasson S. Use of both oral and nasal sumatriptan (Imitrex) during a 24 hr. period in the treatment of migraine [abstract]. Headache 1999;39:349.
26. Kaniecki RG. Mixing Imitrex: a prospective study of stratified care using multiple formulations of sumatriptan [abstract]. Headache 1999;39:361.
27. 1B/1D receptor agonists in migraine. Comparative pharmacology and its therapeutic implications. Central Nerv System Drugs 1998;10:271-86.
28. Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998;51:773-81.
29. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999;19:232-40.
30. Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 2000;20:233-43.
31. Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 1999;19:525-30.
32. Adelman JU, Mannix LK, Von Seggern RL. Rizatriptan tablet versus wafer: patient preference. Headache 2000;40:371-2.
33. Rapoport AM, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. Central Nerv System Drugs 1997;7:37-46.
34. Ashford E, Salonen R Saiers J, Woessner M. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 1998;18:273-7.
35. Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 1998;7:234-40.
36. Dahlof CGH, Boes-Hansen S, Cederberg C-G, Hardebo J-E, Henriksson A. How does sumatriptan nasal spray perform in clinical practice? Cephalalgia 1998;18:278-82.
37. O'Quinn S, Salonen R. Sumatriptan nasal spray compared with intranasal dihydroergotamine in the acute treatment of migraine: results of a comparator trial [abstract]. Headache 1998;38:396.
38. Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ, et al. Transnasal butorphanol in the treatment of acute migraine. Headache 1995;35:65-9.
39. Maizels M, Scott B, Cohen W, Chen W. Intranasal lidocaine for the treatment of migraine. A randomized, double-blind, controlled trial. JAMA 1996;276:319-21.
40. Kunka RL, Hussey EK, Shaw S, Warner P, Aubert B, Richard I, et al. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia 1997;17:532-40.
41. Jones EB, Gonzalez ER, Boggs JG, Grillo JA, Elswick RK Jr. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med 1994;24:237-41.